Why the study?
Does sacubitril/valsartan reduce the rate of eGFR decrease and improve cardiovascular outcomes compared to enalapril in patients with heart failure?
Does sacubitril/valsartan reduce the rate of eGFR decrease and improve cardiovascular outcomes compared to enalapril in patients with heart failure?
Sacubitril/valsartan provides renoprotective effects by slowing eGFR decline while improving cardiovascular outcomes in heart failure patients compared to enalapril.
No takes yet. Share an insight, caveat, or question.
May favor sacubitril/valsartan in HF with renal concerns; leaves open confirmation in dedicated renal-outcome trials.
Damman et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: